Want to see SG:9G2 full AI Analyst Report?
Top Page
Singapore Institute of Advanced Medicine Holdings Ltd.
(SGX:9G2)
Select Model
Select Model
Rating:41Neutral
Price Target:
S$0.03
▼(-6.67% Downside)
Action:Reiterated
Date:09/12/26
The score is held down primarily by weak financial performance: persistent heavy losses, a material 2026 revenue decline, and ongoing negative operating/free cash flow that elevates funding risk. Technicals add modest pressure due to the price sitting below longer-term moving averages and slightly negative MACD, while valuation offers limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Strong Gross Margin
A gross margin of about 92% indicates the underlying medical service offering has attractive direct economics. If revenue stabilizes, this margin profile could provide meaningful operating leverage, although the company must still address overhead and other costs that currently absorb the gross profit.
Negative Factors
Severe Unprofitability
Persistent, very large losses relative to revenue indicate that high gross margins are being overwhelmed by overhead and other costs. This weak profitability limits retained capital, reduces the ability to fund expansion internally, and leaves the business vulnerable if revenue does not recover.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Gross Margin
A gross margin of about 92% indicates the underlying medical service offering has attractive direct economics. If revenue stabilizes, this margin profile could provide meaningful operating leverage, although the company must still address overhead and other costs that currently absorb the gross profit.
Read all positive factors
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) vs. iShares MSCI Singapore ETF (EWS)
Market Cap
S$46.55M
Dividend YieldN/A
Average Volume (3M)1.21M
Price to Earnings (P/E)―
Beta (1Y)-0.40
Revenue Growth-1.27%
EPS Growth16.67%
CountrySG
Employees105
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume1,642,610
30 Day Avg. Volume1,210,063
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.70
Price to Sales (P/S)2.35
P/FCF Ratio-8.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Singapore Institute of Advanced Medicine Holdings Ltd. Business Overview & Revenue Model
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services....
How the Company Makes Money
null...
Singapore Institute of Advanced Medicine Holdings Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.72M | 15.71M | 16.65M | 16.23M | 13.81M |
| Gross Profit | 14.50M | 14.42M | 15.36M | -2.60M | -4.31M |
| EBITDA | -8.97M | -11.08M | -13.42M | -10.60M | -8.02M |
| Net Income | -23.90M | -26.16M | -37.45M | -18.07M | -12.43M |
Balance Sheet | |||||
| Total Assets | 132.10M | 124.71M | 138.76M | 159.52M | 174.36M |
| Cash, Cash Equivalents and Short-Term Investments | 15.18M | 2.84M | 3.16M | 11.05M | 15.84M |
| Total Debt | 61.28M | 58.21M | 46.10M | 80.77M | 87.30M |
| Total Liabilities | 79.18M | 69.07M | 57.01M | 114.60M | 120.31M |
| Stockholders Equity | 52.92M | 55.64M | 81.74M | 44.93M | 54.05M |
Cash Flow | |||||
| Free Cash Flow | -4.14M | -10.78M | -14.80M | -19.89M | -11.26M |
| Operating Cash Flow | -3.65M | -10.63M | -14.26M | -5.45M | -7.15M |
| Investing Cash Flow | -67.04K | 113.13K | -263.72K | -1.45M | 3.72M |
| Financing Cash Flow | 15.83M | 10.20M | 6.64M | 2.11M | 9.18M |
Singapore Institute of Advanced Medicine Holdings Ltd. Technical Analysis
Negative
0.03
Price Trends
0.03
Positive
0.03
Negative
0.04
Negative
Market Momentum
>-0.01
Negative
47.34
Neutral
78.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:9G2, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.04, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.34 is Neutral, neither overbought nor oversold. The STOCH value of 78.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:9G2.
Singapore Institute of Advanced Medicine Holdings Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | S$53.83M | 8.27 | 29.03% | 5.94% | 1.42% | -17.12% | |
66 Neutral | S$1.57B | 22.95 | 6.42% | 3.57% | -3.18% | 6.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | S$1.43B | -44.17 | -6.42% | 0.73% | 6.44% | 38.89% | |
41 Neutral | S$46.55M | -0.91 | -73.80% | ― | -1.27% | 16.67% |
* Healthcare Sector Average
SG:9G2
Singapore Institute of Advanced Medicine Holdings Ltd.
0.03
>-0.01
-9.37%
SG:BSL
Raffles Medical Group
0.84
-0.14
-14.20%
SG:A50
Thomson Medical Group Ltd.
0.05
>-0.01
-10.17%
SG:1B1
HC Surgical Specialists Ltd
0.35
0.02
7.69%
SG:40T
ISEC Healthcare Ltd
0.31
-0.04
-12.18%
SG:5WA
OUE Lippo Healthcare Limited
0.05
0.02
92.00%
Singapore Institute of Advanced Medicine Holdings Ltd. Corporate Events
Singapore Institute of Advanced Medicine Details Use of S$14.9m Rights Issue Proceeds
Aug 6, 2026
Singapore Institute of Advanced Medicine Holdings Ltd. has provided an update on the deployment of approximately S$14.94 million in net proceeds from its renounceable non-underwritten rights cum warrants issue. The company reports that about S$7.1...
Singapore Institute of Advanced Medicine Revamps Board After Chairman Resigns
Jul 14, 2026
Singapore Institute of Advanced Medicine Holdings Ltd. has announced changes to its board and board committees following the resignation of Chairman and Independent Director Mr. Khoo Tiam Hock Vernon, effective 31 July 2026. His departure also inc...
Singapore Institute of Advanced Medicine Expands Capital Base with Rights and Warrants Issue
Jun 24, 2026
Singapore Institute of Advanced Medicine Holdings has completed a renounceable non-underwritten rights-cum-warrants issue, allotting 492,597,856 rights shares and an equal number of warrants, increasing its issued share base from about 1.23 billio...
Singapore Institute of Advanced Medicine Raises S$14.94 Million in Oversubscribed Rights-Cum-Warrants Issue
Jun 23, 2026
Singapore Institute of Advanced Medicine Holdings has successfully completed a renounceable non-underwritten rights-cum-warrants issue that was significantly oversubscribed, receiving valid acceptances and excess applications for about 589.9 milli...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.